Wall Street analysts expect that Opko Health Inc. (NASDAQ:OPK) will post ($0.08) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Opko Health’s earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.07). Opko Health also posted earnings of ($0.08) per share in the same quarter last year. The firm is scheduled to report its next earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Opko Health will report full-year earnings of ($0.24) per share for the current financial year, with EPS estimates ranging from ($0.30) to ($0.14). For the next fiscal year, analysts forecast that the business will report earnings of ($0.26) per share, with EPS estimates ranging from ($0.34) to ($0.21). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Opko Health.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.06. Opko Health had a negative return on equity of 9.32% and a negative net margin of 31.73%. The firm had revenue of $263.69 million for the quarter, compared to analysts’ expectations of $260.37 million.

A number of equities analysts have commented on OPK shares. ValuEngine raised shares of Opko Health from a “strong sell” rating to a “sell” rating in a report on Thursday, July 12th. BidaskClub upgraded Opko Health from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 3rd. Cantor Fitzgerald restated a “buy” rating and set a $20.00 target price on shares of Opko Health in a report on Tuesday, August 7th. Finally, Barrington Research reaffirmed a “buy” rating and set a $7.00 price target on shares of Opko Health in a research note on Wednesday, May 9th. Two research analysts have rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $10.95.

In related news, CEO Phillip Md Et Al Frost acquired 100,000 shares of the stock in a transaction dated Friday, May 18th. The stock was purchased at an average cost of $4.04 per share, with a total value of $404,000.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $12,398,562.04. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. In the last quarter, insiders bought 562,719 shares of company stock worth $2,541,630. Corporate insiders own 42.74% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in OPK. Northern Trust Corp grew its stake in shares of Opko Health by 4.0% during the first quarter. Northern Trust Corp now owns 1,750,676 shares of the biotechnology company’s stock valued at $5,549,000 after buying an additional 66,562 shares during the last quarter. Raymond James & Associates lifted its holdings in shares of Opko Health by 36.4% during the fourth quarter. Raymond James & Associates now owns 332,514 shares of the biotechnology company’s stock valued at $1,629,000 after purchasing an additional 88,725 shares during the last quarter. Teachers Advisors LLC lifted its holdings in shares of Opko Health by 3.5% during the fourth quarter. Teachers Advisors LLC now owns 489,837 shares of the biotechnology company’s stock valued at $2,400,000 after purchasing an additional 16,675 shares during the last quarter. Guggenheim Capital LLC raised its holdings in Opko Health by 800.4% in the 4th quarter. Guggenheim Capital LLC now owns 605,609 shares of the biotechnology company’s stock worth $2,967,000 after acquiring an additional 538,349 shares during the last quarter. Finally, Essex Investment Management Co. LLC raised its holdings in Opko Health by 3.5% in the 2nd quarter. Essex Investment Management Co. LLC now owns 285,700 shares of the biotechnology company’s stock worth $1,343,000 after acquiring an additional 9,697 shares during the last quarter. 23.55% of the stock is owned by institutional investors and hedge funds.

Opko Health traded down $0.08, hitting $5.42, during trading hours on Friday, according to Marketbeat. 6,292,497 shares of the stock were exchanged, compared to its average volume of 7,250,249. Opko Health has a 12 month low of $2.66 and a 12 month high of $7.24. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.94 and a current ratio of 1.05.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

See Also: Earnings Per Share (EPS) Explained

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.